Sudeep Pharma (BOM:544619) Beneish M-Score: 1.42 (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544619 Sudeep Pharma Ltd BOM:544619
21 GF Score
Price ₹1,154.95
! 8 Warning Signs
View Full Analysis

What is Sudeep Pharma Beneish M-Score?

Sudeep Pharma BOM:544619 +4.41% 21 Beneish M-Score is 1.42 as of Sep. 20, 2026. GuruFocus rates BOM:544619 with a GF Score™ of 21/100. The stock has 8 warning signs investors should review. Among 919 Drug Manufacturers companies, Sudeep Pharma ranks worse than 96.08% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 1.42 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Sudeep Pharma's Beneish M-Score or its related term are showing as below:

BOM:544619' s Beneish M-Score Range Over the Past 10 Years
Min: -1.8   Med: -1.8   Max: 1.42
Current: 1.42

During the past 5 years, the highest Beneish M-Score of Sudeep Pharma was 1.42. The lowest was -1.80. And the median was -1.80.

Sudeep Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sudeep Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sudeep Pharma Beneish M-Score Chart

Sudeep Pharma Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
- -2.43 -1.21 -1.81 0.81

Sudeep Pharma Quarterly Data
Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial - - - - -

BOM:544619 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sudeep Pharma Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sudeep Pharma's Beneish M-Score falls into.


BOM:544619
21GF Score
Sudeep Pharma Ltd BOM:544619
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sudeep Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sudeep Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0922+0.528 * 1.0413+0.404 * 7.0116+0.892 * 1.2843+0.115 * 1.1256
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0238+4.679 * 0.094513-0.327 * 0.6719
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹2,721 Mil.
Revenue was ₹6,388 Mil.
Gross Profit was ₹3,169 Mil.
Total Current Assets was ₹6,240 Mil.
Total Assets was ₹11,776 Mil.
Property, Plant and Equipment(Net PPE) was ₹4,524 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹148 Mil.
Selling, General, & Admin. Expense(SGA) was ₹1,002 Mil.
Total Current Liabilities was ₹2,020 Mil.
Long-Term Debt & Capital Lease Obligation was ₹356 Mil.
Net Income was ₹1,729 Mil.
Gross Profit was ₹ Mil.
Cash Flow from Operations was ₹616 Mil.
 Total Receivables was ₹1,940 Mil.
Revenue was ₹4,974 Mil.
Gross Profit was ₹2,569 Mil.
Total Current Assets was ₹4,241 Mil.
Total Assets was ₹7,192 Mil.
Property, Plant and Equipment(Net PPE) was ₹2,863 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹106 Mil.
Selling, General, & Admin. Expense(SGA) was ₹762 Mil.
Total Current Liabilities was ₹1,748 Mil.
Long-Term Debt & Capital Lease Obligation was ₹412 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2721.056 / 6388.014) / (1939.899 / 4974.078)
=0.425963 / 0.390002
=1.0922

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2569.489 / 4974.078) / (3168.896 / 6388.014)
=0.516576 / 0.496069
=1.0413

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6239.66 + 4524.292) / 11776.179) / (1 - (4241.204 + 2862.554) / 7191.927)
=0.085955 / 0.012259
=7.0116

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6388.014 / 4974.078
=1.2843

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(105.904 / (105.904 + 2862.554)) / (148.085 / (148.085 + 4524.292))
=0.035676 / 0.031694
=1.1256

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1002.063 / 6388.014) / (762.12 / 4974.078)
=0.156866 / 0.153218
=1.0238

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((356.229 + 2019.625) / 11776.179) / ((412.084 + 1747.569) / 7191.927)
=0.201751 / 0.300289
=0.6719

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1728.926 - 0 - 615.927) / 11776.179
=0.094513

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sudeep Pharma has a M-score of 0.87 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 1.42 mean?
Sudeep Pharma (BOM:544619) has a Beneish M-Score of 1.42 as of Sep. 20, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sudeep Pharma and its competitors. According to the industry distribution chart, Sudeep Pharma ranks #883 out of 919 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is Sudeep Pharma's Beneish M-Score too high?
Sudeep Pharma's current Beneish M-Score is 1.42. Based on the distribution chart, Sudeep Pharma ranks #883 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sudeep Pharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #883 out of 919 companies for Beneish M-Score. This places Sudeep Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sudeep Pharma and its competitors. Sudeep Pharma's current Beneish M-Score is 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Beneish M-Score of 1.42. The current Beneish M-Score is 1.42. Sudeep Pharma's overall GF Score™ is 21/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Beneish M-Score is 1.42 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sudeep Pharma Business Description

Other Exchanges SUDEEPPHRM:India
Address Gotri-Sevasi Road, 601-602, 6th floor, Sears II, East Wing, Towers - 2, Sevasi, Vadodara, GJ, IND, 391101
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
21GF Score

Get the complete analysis for BOM:544619

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,154.95
Price